Clinical manifestations and responsiveness to adalimumab are similar in patients with ankylosing spondylitis with and without concomitant psoriasis

Rheumatology

Volumn 49, Issue 8, 2010, Pages 1578-1589

  Braun, Jürgen ^a   Rudwaleit, Martin ^b   Kary, Sonja ^c   Kron, Martina ^c   Wong, Robert L ^d   Kupper, Hartmut ^c  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c ABBOTT GMBH AND CO KG   (Germany)

^d UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

Adalimumab; Ankylosing spondylitis; Psoriasis; TNF antagonist

Indexed keywords

ADALIMUMAB;

ADULT; ANKYLOSING SPONDYLITIS; ARTHRITIS; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DRUG EFFICACY; ENTHESITIS; FEMALE; HUMAN; JOINT SWELLING; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS; SPINE DISEASE; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; DISABILITY EVALUATION; FEMALE; HUMANS; JOINTS; MALE; MIDDLE AGED; PSORIASIS; SEVERITY OF ILLNESS INDEX; SKIN; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

EID: 77954735314     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq129     Document Type: Article

References (47)

1. Brophy S, Pavy S, Lewis P et al. Inflammatory eye, skin, and bowel disease in spondyloarthritis: genetic, phenotypic, and environmental factors. J Rheumatol 2001;28: 2667-73.
2. Vander Cruyssen B, Ribbens C, Boonen A et al. The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice. Ann Rheum Dis 2007;66:1072-7.
3. Rudwaleit M, Haibel H, Baraliakos X et al. The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort (GESPIC). Arthritis Rheum 2009;60:717-27.
4. Edmunds L, Elswood J, Kennedy LG, Calin A. Primary ankylosing spondylitis, psoriatic and enteropathic spondyloarthropathy: a controlled analysis. J Rheumatol 1991;18:696-8.
5. Fernández-Sueiro JL, Willisch A, Pértega-Díaz S et al. Evaluation of ankylosing spondylitis spinal mobility measurements in the assessment of spinal involvement in psoriatic arthritis. Arthritis Rheum 2009;61:386-92.
6. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54: 2665-73.
7. Gladman DD, Inman RD, Cook RJ et al. International spondyloarthritis interobserver reliability exercise-the INSPIRE study: I. Assessment of spinal measures. J Rheumatol 2007;34:1733-9.
8. Moll JM, Wright V. Chest and spinal movement in ankylosing spondylitis. Rheumatol Rehabil 1974;13:30-1.
9. Dougados M, van der Linden S, Ruhlin R et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991;34:1218-27.
10. Nash P, Mease PJ, Braun J, van der Heijde D. Seronegative spondylarthropathies: to lump or split? Ann Rheum Dis 2005;64(Suppl. 2):ii9-13.
11. Zochling J, van der Heijde D, Burgos-Vargas R et al. Assessment in AS International Working Group. European League against Rheumatism. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006;56:442-52.
12. Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D. ASAS Working Group. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:316-20.
13. van der Heijde D, Kivitz A, Schiff MH et al. Adalimumab Trial Evaluating Long-term Efficacy and Safety for Ankylosing Spondylitis (ATLAS) Study Group. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54:2136-46.
14. Braun J, Brandt J, Listing J et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-93.
15. Braun J, Brandt J, Listing J et al. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 2005;64:229-34.
16. van der Heijde D, Dijkmans B, Geusens P et al. Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582-91.
17. van den Bosch F, Kruithof E, Baeten D et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 2002;46: 755-65.
18. Calin A, Dijkmans BA, Emery P et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004;63:1594-600.
19. Davis JC Jr, van der Heijde D, Braun J et al. Enbrel Ankylosing Spondylitis Study Group. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230-6.
20. Davis JC, van der Heijde DM, Braun J et al. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis 2005;64: 1557-62.
21. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356: 385-90.
22. Mease PJ, Kivitz AJ, Burch FX et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264-72.
23. Antoni CE, Kavanaugh A, Kirkham B et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum 2005;52:1227-36.
24. Antoni C, Krueger GG, de Vlam K et al. IMPACT 2 Trial Investigators. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;64:1150-7.
25. van der Heijde D, Kavanaugh A, Gladman DD et al. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum 2007;56: 2698-707.
26. Mease PJ, Gladman DD, Ritchlin CT et al. Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279-89.
27. Gladman DD, Mease PJ, Ritchlin CT et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial. Arthritis Rheum 2007;56:476-88.
28. Ritchlin CT, Kavanaugh A, Gladman DD et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009;68:1387-94.
29. Rudwaleit M, Claudepierre P, Wordsworth P et al. Effectiveness, safety, and predictors of good clinical response in 1,250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol 2009;36:801-8.
30. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
31. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21: 2286-91.
32. Rudwaleit M, Rødevand E, Holck P et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 2009;68: 696-701.
33. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876-86.
34. Furst DE, Keystone EC, Kirkham B et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 2008;67(Suppl. 3):iii2-25.
35. Calin A, Garrett S, Whitelock H et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
36. Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 1994;21:1694-8.
37. Kosinski M, Keller SD, Hatoum HT, Kong SX, Ware JE Jr. The SF-36 Health Survey as a generic outcome measure in clinical trials of patients with osteoarthritis and rheumatoid arthritis: tests of data quality, scaling assumptions and score reliability. Med Care 1999; 37(5 Suppl.):MS10-22.
38. Gladman DD, Helliwell P, Mease PJ, Nash P, Ritchlin C, Taylor W. Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum 2004;50:24-35.
39. Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003;62:127-32.
40. Rojas-Vargas M, Muñoz-Gomariz E, Escudero A et al. First signs and symptoms of spondyloarthritis-data from an inception cohort with a disease course of two years or less (REGISPONSER-Early). Rheumatology 2009;48:404-9.
41. van den Bosch F, Manger B, Goupille P et al. Adalimumab (Humira®) is effective in treating patients with psoriatic arthritis (PsA) in real-life clinical practice: results of the STEREO trial. Ann Rheum Dis 2007;66(Suppl. II):98.
42. Harrison MJ, Dixon WG, Watson KD et al. British Society for Rheumatology Biologics Register Control Centre Consortium. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2009; 68:209-15.
43. Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat 2009;20: 100-8.
44. Grinblat B, Scheinberg M. The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: a review. Semin Arthritis Rheum 2008;37:251-5.
45. Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 2008;59:996-1001.
46. de Gannes GC, Ghoreishi M, Pope J et al. Psoriasis and pustular dermatitis triggered by TNF-alpha inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007;143:223-31.
47. Dass S, Vital EM, Emery P. Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum 2007;56: 2715-8.